Home/Pipeline/Undisclosed Whole Cell Vaccine Program(s)

Undisclosed Whole Cell Vaccine Program(s)

Solid Tumors

Pre-clinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

Active

Company

Neuvogen

About Neuvogen

Neuvogen is a private, preclinical-stage biotech founded in 2015 and headquartered in San Diego, CA, USA. The company is pioneering a novel whole tumor cell vaccine platform designed to overcome the heterogeneity of solid tumors by eliciting a broad, multi-antigen T-cell response. Led by a team with expertise in oncology, immunology, and biotech finance, Neuvogen aims to create accessible, off-the-shelf vaccines that can be integrated into standard care to prevent relapse. The company is currently in the preclinical development phase and is pre-revenue.

View full company profile

Therapeutic Areas

Oncology Solid Tumors

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed